Mesoblast’s Heart Treatment Revascor Secures FDA RMAT Status for Rare Pediatric Heart Condition | MESO Stock News

Published: 12/05/2024

Mesoblast’s Heart Treatment Revascor Secures FDA RMAT Status for Rare Pediatric Heart Condition | MESO Stock News

tags

Latest News

NEWS 03.05.2026

Government Hosts Youth Engagement Conference in Bengaluru – Observer Voice

NEWS 03.05.2026

Polycythemia Market Expected to Reach $6.53 Billion by 2030 – Comprehensive Report from The Business Research Company – Weekly Voice

NEWS 03.05.2026

Longevity And Anti-Senescence Therapy Market 2026: Unlock Breakthrough Therapies Extending Healthy Lifespan – Weekly Voice

NEWS 03.05.2026

Leading celebrity surgeon Dr Matee Rajput redefines modern ageing with expansion into elite wellness, longevity medicine and aesthetics – London Daily News